Investor Portal & SHARE magazine

Access Novo Nordisk Investor Portal (UK)

Log på Novo Nordisk Investor Portal (DK)

The Investor Portal is administered by VP Securities A/S. VP Securities A/S is a Central Securities Depository (CSD) in Denmark authorised by the Danish Financial Supervisory Authority (Finanstilsynet) according to the Danish Securities Trading Act. Learn how VP Securities A/S process personal data.

For further information, please refer to our Notice of Personal Data Processing.

This also applies to notices to convene general meetings which will no longer be sent to shareholders as hardcopy by regular mail.

Shareholders are encouraged to sign up and register their email address via Novo Nordisk A/S’ InvestorPortal

Shareholders who wish to receive company information are responsible for ensuring that Novo Nordisk A/S is in possession of the correct email address and should sign up via the InvestorPortal. Learn more about how to sign-up your email.

Receipt of electronic communication from Novo Nordisk requires access to an email and a pdf-viewer.

Announcements of a general nature will be made available at novonordisk.com.

Holders of such certificates were thus encouraged to contact Danske Bank, Corporate Actions, via contact details below no later than 4 November 2018 in order to have their shareholdings registered and the physical certificates converted into registered shares in Novo Nordisk A/S and Novozymes A/S.

If the conversion was not completed by 4 November 2018, the corresponding shares have been sold pursuant to the Danish Companies Act. Holders of physical share certificates and interim certificates will be entitled to collect the net proceeds of the share sale within a period of three years following the sale.

See the announcement as published on Virk.dk for further information (in Danish).

The above applies to holders of physical share certificates and interim certificates in former Nordisk Gentofte A/S and Novo Industri A/S only and does not affect shareholders of registered shares in Novo Nordisk A/S.

Danske Bank, 3886 Corporate Actions,
Holmens Kanal 2-12, 1092 København K,
Telephone: (+45) 45 14 36 94
E-mail: corporate.actions@danskebank.dk

The total dividend for 2019 was DKK 8.35 for each A and B share, consisting of an interim dividend of DKK 3.00 (paid in August 2019) and a final dividend of DKK 5.35 (paid in March 2020) for each A and B share.

The interim dividend for 2020 of DKK 3.25 for each A and B share of DKK 0.20 was paid in August 2020.

The share buyback programme is a way for Novo Nordisk to return excess capital to the investors. By buying back shares and reducing the share capital, the value of the remaining outstanding shares increases.

The Annual General Meeting 2019 took place 21 March 2019.

The Annual General Meeting 2020 took place 26 March 2020.

You can look up and download historical share prices in the Shareholder tools section. You can also calculate the return on the investment you have made in Novo Nordisk shares

No – we will automatically get your new address.

In our InvestorPortal guideline (pdf) you can learn how to add or update your email address.

Access Novo Nordisk Investor Portal (UK)

Log på Novo Nordisk Investor Portal (DK)

ADR is an abbreviation for an American Depository Receipt. An ADR is a receipt for the shares of a foreign-based corporation held in the vault of a U.S. bank, entitling the shareholder to all dividends and capital gains.

The depository bank responsible for Novo Nordisk’s ADR is JP Morgan and the contact information is:

J.P. Morgan
1 Chase Manhattan Plaza, Floor 58
New York, NY 10005
(866) JPM-ADRS (866 576-2377)
adr@jpmorgan.com

Q2 2021

SHARE Magazine UK | SHARE Magazine DK

Index

Message from the CEO
New stem cell partnership targets chronic heart failure
Ozempic® approved in China
Novo Nordisk teams up with the University of Toronto to kickstart a new era in preventive public health
Stepping up the game in obesity treatment: Wegovy^TM approved in the US

Q1 2021

SHARE Magazine UK | SHARE Magazine DK

Index

Message from the CEO
R&D organisation evolves into two areas
Oral semaglutide set to enter phase 3 development for Alzheimer’s disease
Digital health: first smart pens launched in Sweden
Rybelsus® launched in Japan – one of the world’s largest oral anti-diabetes markets

Q3 2020

SHARE Magazine UK | SHARE Magazine DK

Index

Message from the CEO
Phase 2 trial successfully completed with ziltivekimab
Raised 2020 outlook on 8 October 2020
Not if, but how: new strategy steps up our efforts to Defeat Diabetes
100% renewable power target for direct suppliers launched in 2020
100 years ‎young: why we’re investing in the future of insulin

Q2 2020

SHARE Magazine UK | SHARE Magazine DK

Index

Message from the CEO
Clinical results support Strategic Aspiration for obesity treatment
Novo Nordisk acquires Corvidia Therapeutics and expands presence in cardiovascular disease
Lose or reuse? How we are repurposing our insulin pens
A deep dive into NASH and Novo Nordisk’s activities in tackling this disease
Highlights from the first six months of 2020